Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Personalis Inc (PSNL)

Personalis Inc (PSNL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 65,655
  • Shares Outstanding, K 50,504
  • Annual Sales, $ 73,480 K
  • Annual Income, $ -108,300 K
  • 60-Month Beta 1.95
  • Price/Sales 0.95
  • Price/Cash Flow N/A
  • Price/Book 0.49
Trade PSNL with:

Options Overview Details

View History
  • Implied Volatility 297.19% ( -23.27%)
  • Historical Volatility 59.78%
  • IV Percentile 68%
  • IV Rank 23.15%
  • IV High 1,157.51% on 10/20/23
  • IV Low 38.09% on 06/06/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 739
  • Open Int (30-Day) 1,152

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.44
  • Number of Estimates 2
  • High Estimate -0.36
  • Low Estimate -0.52
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +27.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1800 +10.17%
on 04/18/24
1.5400 -15.58%
on 04/01/24
-0.1200 (-8.45%)
since 03/22/24
3-Month
1.1200 +16.07%
on 02/08/24
1.8000 -27.78%
on 03/13/24
-0.2700 (-17.20%)
since 01/24/24
52-Week
0.8906 +45.97%
on 11/10/23
2.6000 -50.00%
on 06/06/23
-1.0600 (-44.92%)
since 04/24/23

Most Recent Stories

More News
Personalis: Q4 Earnings Snapshot

Personalis: Q4 Earnings Snapshot

PSNL : 1.3000 (-5.80%)
Personalis: Q3 Earnings Snapshot

Personalis: Q3 Earnings Snapshot

PSNL : 1.3000 (-5.80%)
Personalis: Q2 Earnings Snapshot

Personalis: Q2 Earnings Snapshot

PSNL : 1.3000 (-5.80%)
Personalis: Q1 Earnings Snapshot

Personalis: Q1 Earnings Snapshot

PSNL : 1.3000 (-5.80%)
Personalis Reports First Quarter 2023 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2023 and provided recent business highlights....

PSNL : 1.3000 (-5.80%)
Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer

Personalis, Inc. (Nasdaq: PSNL) today announced it has partnered with the Academic Breast Cancer Consortium (ABRCC) and Criterium to carry out a prospective clinical trial, B-STRONGER-1 (Breast Cancer-Minimal...

PSNL : 1.3000 (-5.80%)
Personalis to Announce First Quarter 2023 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2023 financial results on Wednesday, May 3, 2023. In conjunction...

PSNL : 1.3000 (-5.80%)
Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference...

PSNL : 1.3000 (-5.80%)
Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study

Personalis, Inc. (Nasdaq: PSNL), Cancer Research UK’s Cancer Research Horizons, University College London (UCL), and the Francis Crick Institute today announced a collaboration to deploy NeXT Personal...

PSNL : 1.3000 (-5.80%)
Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023

Personalis, Inc. (Nasdaq: PSNL) today announced it is presenting new research data as scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2023, which convenes from...

PSNL : 1.3000 (-5.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.

See More

Key Turning Points

3rd Resistance Point 1.4333
2nd Resistance Point 1.4067
1st Resistance Point 1.3533
Last Price 1.3000
1st Support Level 1.2733
2nd Support Level 1.2467
3rd Support Level 1.1933

See More

52-Week High 2.6000
Fibonacci 61.8% 1.9470
Fibonacci 50% 1.7453
Fibonacci 38.2% 1.5436
Last Price 1.3000
52-Week Low 0.8906

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar